Ildong Pharmaceutical, operating profit of 10.5 billion won in the third quarter…successful return to profit

Ildong Pharmaceutical announced on the 30th that its provisional operating profit, based on separate financial statements for the third quarter, had turned into a surplus at 10.5 billion won. The company’s operating loss in the same period last year was 16.1 billion won. Operating profit has continued to turn into surplus since the fourth quarter of last year.

Third quarter sales were recorded at KRW 154.6 billion, a 3.6% increase compared to the same period last year. Net profit for the period was 4.3 billion won, turning into a surplus compared to the same period last year.

The company explained that securing the original copyright for new drugs and diversifying its portfolio through co-promotion were instrumental in improving its performance. Sales of ‘Pirespa’, a treatment for idiopathic pulmonary fibrosis, recorded 32.2 billion won, up 8.6% compared to the same period last year. Pyrespa is a drug developed by Shinoogi Pharmaceutical, and Ildong Pharmaceutical secured the copyright in 2012 and is selling it. Sales of ‘Moti Liton’, a digestive medicine drug jointly sold by Ildong Pharmaceutical and Dong-A ST, increased 9.7% over the same period to 28.3 billion won.

Consumer healthcare performance also grew. Sales of the multivitamin ‘Aronamin’ series rose from KRW 38.8 billion to KRW 45.3 billion in the third quarter of last year, driving performance growth. In addition, the company explained that probiotics ‘GQ Lab’ and ‘BioVita’ also showed high growth of 14.0% and 21.9%, respectively, over the same period.